Aliases & Classifications for Vaccinia

MalaCards integrated aliases for Vaccinia:

Name: Vaccinia 12 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3298
MeSH 45 D014615
UMLS 74 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted by contact with the vaccination site before it has healed, or transmitted by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to cowpox and variola major, and has symptoms including fever, rash and body aches. An important gene associated with Vaccinia is VRK1 (VRK Serine/Threonine Kinase 1), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and skin, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Diseases related to Vaccinia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 cowpox 11.5
2 variola major 10.8
3 smallpox 10.8
4 influenza 10.5
5 hepatitis 10.4
6 melanoma 10.4
7 encephalitis 10.4
8 chromosome 2p16.1-p15 deletion syndrome 10.4 BANF1 VRK2
9 monkeypox 10.4
10 human immunodeficiency virus type 1 10.3
11 dermatitis 10.3
12 malaria 10.3
13 rabies 10.3
14 blood group--wright antigen 10.3
15 hepatitis c 10.3
16 hepatitis c virus 10.3
17 stomatitis 10.3
18 herpes simplex 10.2
19 breast cancer 10.2
20 deafness-infertility syndrome 10.2
21 japanese encephalitis 10.2
22 severe acute respiratory syndrome 10.2
23 measles 10.2
24 hepatocellular carcinoma 10.2
25 pancreatic cancer 10.2
26 prostate cancer 10.1
27 prostate cancer, hereditary, 8 10.1
28 prostate cancer, hereditary, 6 10.1
29 hepatitis b 10.1
30 glioma 10.1
31 murray valley encephalitis 10.1 ERVW-1 IL2
32 colorectal cancer 10.1
33 dermatitis, atopic 10.1
34 adenocarcinoma 10.1
35 eczema herpeticum 10.1 IRF3 IRF7
36 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.1
37 leukemia 10.1
38 leishmaniasis 10.1
39 yellow fever 10.1
40 t-cell adult acute lymphocytic leukemia 10.1 ERVW-1 IL2
41 fibroma 10.1
42 lymphocytic choriomeningitis 10.1
43 molluscum contagiosum 10.1
44 noonan syndrome 3 10.0
45 mumps 10.0
46 sarcoma 10.0
47 newcastle disease 10.0
48 venezuelan equine encephalitis 10.0
49 alzheimer disease 10.0
50 ovarian cancer 10.0

Graphical network of the top 20 diseases related to Vaccinia:



Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia

Symptoms:

12
  • fever
  • rash
  • body aches

MGI Mouse Phenotypes related to Vaccinia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 AZI2 BTRC DUSP3 EIF2AK2 EPS15 IL2
2 immune system MP:0005387 9.32 AZI2 BTRC EIF2AK2 EPS15 IL2 IRF3

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
2 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
4 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
5 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Phase 1
6 gamma-Globulins Phase 4,Phase 3,Phase 2,Phase 1
7 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
8
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
9
Carboplatin Approved Phase 2, Phase 3,Not Applicable 41575-94-4 10339178 38904 498142
10
Cisplatin Approved Phase 2, Phase 3,Phase 1 15663-27-1 2767 441203 84093
11
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 33069-62-4 36314
12
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
13
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
14
Pemetrexed Approved, Investigational Phase 2, Phase 3 150399-23-8, 137281-23-3 60843 446556
15
leucovorin Approved Phase 2, Phase 3 58-05-9 143 6006
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
17 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
19 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
20 Anticonvulsants Phase 3
21 Analgesics Phase 3,Phase 2,Phase 1
22 Neurotropin Phase 3
23 polysaccharide-K Phase 3,Phase 2,Phase 1
24 Iron-Dextran Complex Phase 3,Phase 2
25 Protein Kinase Inhibitors Phase 3,Phase 2
26 Antimitotic Agents Phase 2, Phase 3,Phase 1
27 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
28 Antimetabolites Phase 2, Phase 3,Phase 1
29 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
30 Antiviral Agents Phase 2, Phase 3,Phase 1
31 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 1,Not Applicable
32 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
33 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 1
34 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
35 Vitamin B Complex Phase 2, Phase 3
36 Folic Acid Antagonists Phase 2, Phase 3
37 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
38
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
39 Folate Phase 2, Phase 3
40 Vitamin B9 Phase 2, Phase 3
41 Antineoplastic Agents, Phytogenic Phase 2, Phase 3
42
Sargramostim Approved, Investigational Phase 1, Phase 2,Phase 2 123774-72-1, 83869-56-1
43
Metronidazole Approved Phase 2,Phase 1,Not Applicable 443-48-1 4173
44
Bicalutamide Approved Phase 2 90357-06-5 2375 56069
45
Goserelin Approved Phase 2 65807-02-5 5311128 47725
46
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
47
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 43805 6857599 5310940 9887054
48
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
49
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
50
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2

Interventional clinical trials:

(show top 50) (show all 262)
# Name Status NCT ID Phase Drugs
1 Special Access Program IMVAMUNE® Completed NCT03472014 Phase 4
2 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
3 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
4 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
5 VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV Completed NCT01158157 Phase 3
6 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
7 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
8 Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
9 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
10 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
11 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Recruiting NCT02562755 Phase 3 Sorafenib
12 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
13 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
14 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Active, not recruiting NCT02509494 Phase 3
15 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Active, not recruiting NCT02661464 Phase 3
16 Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial Not yet recruiting NCT03699124 Phase 3
17 Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated NCT01383148 Phase 2, Phase 3 placebo
18 Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002817 Phase 1, Phase 2
19 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
20 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
21 A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
22 Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma Completed NCT00116597 Phase 1, Phase 2
23 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT00554372 Phase 2
24 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
25 Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
26 A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
27 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
28 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
29 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2 Bicalutamide;Goserelin Acetate
30 PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer Completed NCT00088413 Phase 1, Phase 2 Sargramostim (GM-CSF, Leukine)
31 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma Completed NCT01394939 Phase 1, Phase 2 Irinotecan
32 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
33 A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib Completed NCT01387555 Phase 2
34 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
35 A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer Completed NCT01636284 Phase 2
36 A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2 JX-594 followed by sorafenib
37 Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer Completed NCT00179309 Phase 2 Docetaxel
38 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
39 Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Completed NCT02919306 Phase 1, Phase 2 Placebo
40 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
41 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00019734 Phase 2
42 Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00054535 Phase 2
43 Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Completed NCT00112957 Phase 2
44 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
45 A Study of MVA85A in Healthy Children and Infants Completed NCT00679159 Phase 2
46 Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors Completed NCT00003125 Phase 2
47 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
48 Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults Completed NCT00820846 Phase 2
49 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
50 Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines Completed NCT01461447 Phase 1, Phase 2

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:

20
Skin

MalaCards organs/tissues related to Vaccinia:

42
T Cells, Skin, B Cells, Testes, Prostate, Nk Cells, Monocytes

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 3258)
# Title Authors Year
1
Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes. ( 30794666 )
2019
2
Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV. ( 30674625 )
2019
3
lncRNA UCA1-Mediated Cdc42 Signaling Promotes Oncolytic Vaccinia Virus Cell-to-Cell Spread in Ovarian Cancer. ( 31011626 )
2019
4
PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma. ( 30885937 )
2019
5
Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. ( 30365143 )
2019
6
Outbreak of Vaccinia Virus Infection from Occupational Exposure, China, 2017. ( 31107220 )
2019
7
Combinatory effects of vaccinia virus VG9 and the STAT3 inhibitor Stattic on cancer therapy. ( 31087190 )
2019
8
Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice. ( 31076161 )
2019
9
A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo. ( 31069131 )
2019
10
Quantitative Temporal Proteomic Analysis of Vaccinia Virus Infection Reveals Regulation of Histone Deacetylases by an Interferon Antagonist. ( 31067474 )
2019
11
Vaccinia-related kinase 2 plays a critical role in microglia-mediated synapse elimination during neurodevelopment. ( 31050055 )
2019
12
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism. ( 31011628 )
2019
13
Recombinant Oncolytic Vaccinia Viruses Expressing Human β-Defensin 2 Enhance Anti-tumor Immunity. ( 31011627 )
2019
14
Asparagine is a critical limiting metabolite for vaccinia virus protein synthesis during glutamine deprivation. ( 30996100 )
2019
15
A genome-wide haploid genetic screen identifies heparan sulfate-associated genes and the macropinocytosis modulator TMED10 as factors supporting vaccinia virus infection. ( 30996093 )
2019
16
By binding CD80 and CD86, the vaccinia virus' M2 protein blocks their interactions with both CD28 and CTLA4 and potentiates CD80's binding to PD-L1. ( 30918073 )
2019
17
Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers. ( 30917829 )
2019
18
The Perennial Use of the Green Fluorescent Protein Marker in a Live Vaccinia Virus Ankara Recombinant Platform Shows No Acute Adverse Effects in Mice. ( 30877662 )
2019
19
Selection of Vaccinia Virus-Neutralizing Antibody from a Phage-Display Human-Antibody Library. ( 30856707 )
2019
20
Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. ( 30851967 )
2019
21
NF-κB activation is a turn on for vaccinia virus phosphoprotein A49 to turn off NF-κB activation. ( 30819886 )
2019
22
Molecular basis of cullin-3 (Cul3) ubiquitin ligase subversion by vaccinia virus protein A55. ( 30819806 )
2019
23
Vaccinia virus BBK E3 ligase adaptor A55 targets importin-dependent NF-κB activation and inhibits CD8+ T-cell memory. ( 30814284 )
2019
24
Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus. ( 30760570 )
2019
25
Differential Response Following Infection of Mouse CNS with Virulent and Attenuated Vaccinia Virus Strains. ( 30759813 )
2019
26
Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity. ( 30719592 )
2019
27
Species-specific inhibition of antiviral protein kinase R by capripoxviruses and vaccinia virus. ( 30644558 )
2019
28
Proteomics Analysis Reveals That Structural Proteins of the Virion Core and Involved in Gene Expression Are the Main Source for HLA Class II Ligands in Vaccinia Virus-Infected Cells. ( 30629447 )
2019
29
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. ( 30626434 )
2019
30
The Vaccinia virion: Filling the gap between atomic and ultrastructure. ( 30615658 )
2019
31
Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. ( 30538109 )
2019
32
HNRNP Q suppresses polyglutamine huntingtin aggregation by post-transcriptional regulation of vaccinia-related kinase 2. ( 30488434 )
2019
33
The Ectodomain of the Vaccinia Virus Glycoprotein A34 Is Required for Cell Binding by Extracellular Virions and Contains a Large Region Capable of Interaction with Glycoprotein B5. ( 30463966 )
2019
34
Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility. ( 30420785 )
2019
35
Oncolytic cancer therapy with a vaccinia virus strain. ( 30365140 )
2019
36
A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. ( 29581442 )
2018
37
Haliotis discus discus Sialic Acid-Binding Lectin Reduces the Oncolytic Vaccinia Virus Induced Toxicity in a Glioblastoma Mouse Model. ( 29701680 )
2018
38
Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression. ( 30096846 )
2018
39
Antiviral activity of metal chelates of caffeic acid and similar compounds towards herpes simplex, VSV-Ebola pseudotyped and vaccinia viruses. ( 30393014 )
2018
40
A Novel System for Constructing a Recombinant Highly-Attenuated Vaccinia Virus Strain (LC16m8) Expressing Foreign Genes and Its Application for the Generation of LC16m8-Based Vaccines against Herpes Simplex Virus 2. ( 29709968 )
2018
41
Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial. ( 29912453 )
2018
42
Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus. ( 30410347 )
2018
43
A comparison of the effect of molluscum contagiosum virus MC159 and MC160 proteins on vaccinia virus virulence in intranasal and intradermal infection routes. ( 29393023 )
2018
44
E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox. ( 29300297 )
2018
45
Phototracking Vaccinia Virus Transport Reveals Dynamics of Cytoplasmic Dispersal and a Requirement for A36R and F12L for Exit from the Site of Wrapping. ( 30042325 )
2018
46
Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. ( 30045984 )
2018
47
RNA Polymerase Mutations Selected during Experimental Evolution Enhance Replication of a Hybrid Vaccinia Virus with an Intermediate Transcription Factor Subunit Replaced by the Myxoma Virus Ortholog. ( 30045995 )
2018
48
N-terminal domain of Schmallenberg virus envelope protein Gc delivered by recombinant equine herpesvirus type 1 and modified vaccinia virus Ankara: Immunogenicity and protective efficacy in cattle. ( 30049630 )
2018
49
Vaccinia-related kinase 2 modulates role of dysbindin by regulating protein stability. ( 30062698 )
2018
50
Ebola virus - prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine. ( 30092691 )
2018

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

Pathways related to Vaccinia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 BTRC CUL1 CYB5R3 DUSP3 EIF2AK2 IL2
2
Show member pathways
12.74 IL2 IRF3 IRF7 NLRP1 TANK
3
Show member pathways
12.39 AZI2 IRF3 IRF7 TANK TBKBP1
4
Show member pathways
11.87 BTRC CUL1 IRF7 TANK
5 11.61 IL2 IRF3 IRF7 NLRP1 TANK TBKBP1
6
Show member pathways
10.85 BANF1 VRK1 VRK2
7
Show member pathways
10.49 EIF2AK2 IRF3 IRF7

GO Terms for Vaccinia

Cellular components related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.44 BANF1 BTRC CUL1 DUSP3 EIF2AK2 EPS15

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.91 EIF2AK2 IL2 IRF3 IRF7 NLRP1
2 innate immune response GO:0045087 9.88 EIF2AK2 IRF3 IRF7 NLRP1 TBKBP1
3 peptidyl-serine phosphorylation GO:0018105 9.73 VRK1 VRK2 VRK3
4 response to virus GO:0009615 9.7 BANF1 EIF2AK2 IRF7
5 peptidyl-threonine phosphorylation GO:0018107 9.58 VRK1 VRK2 VRK3
6 NIK/NF-kappaB signaling GO:0038061 9.55 BTRC CUL1
7 positive regulation of kinase activity GO:0033674 9.54 IL2 ITSN1
8 positive regulation of interferon-alpha production GO:0032727 9.49 IRF3 IRF7
9 regulation of type I interferon production GO:0032479 9.46 IRF3 IRF7
10 viral process GO:0016032 9.44 AZI2 BANF1 BTRC CUL1 EIF2AK2 EPS15
11 mitotic nuclear envelope reassembly GO:0007084 9.37 BANF1 VRK1
12 MDA-5 signaling pathway GO:0039530 9.32 IRF3 IRF7
13 interferon-alpha production GO:0032607 9.16 AZI2 IRF7
14 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.13 IRF7
15 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.13 IRF3 IRF7 TANK
16 type I interferon biosynthetic process GO:0045351 8.96 IRF7

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 AZI2 BANF1 BTRC CUL1 CYB5R3 EIF2AK2
2 kinase activator activity GO:0019209 8.96 IL2 ITSN1

Sources for Vaccinia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....